1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Oncolys BioPharma Inc.

Oncolys BioPharma Inc.

4588.T
Oncolys BioPharma Inc.JP flagTokyo Stock Exchange
2,540.00
JPY
-82.00
- -
63.21BMarket Cap
Oncolys BioPharma Inc.
4588.T
(Tokyo Stock Exchange)

Recent

price

2,540.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
64.95
0.18
3.14
13.21
19.37
22.32
14.28
93.68
21.83
37.98
56.34
3.54
1.44
1.11
1.57
Revenue per Share
-16.83
-94.33
-80.55
-93.35
-101.18
-106.23
-104.55
-65.55
-145.58
-95.5
-66.31
-108.92
-77.17
-80
-91.36
Basic EPS, GAAP
-27.3
-88.94
-91.29
-82.75
-100.42
-106.97
-100.77
-17.43
-102
-103.06
-99.18
-75.44
-92.69
-75.56
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-321.39
2.65
-77.21
-170.47
-269.22
-278.32
-295.82
-264.77
-379.72
-323.81
90.34
14.05
2.3
89.72
-7.63
Book Value per Share
77.08
755.84
476.4
380.82
284.32
285.56
245.82
248.12
139.16
212.47
124.62
82.83
126.07
155.49
70.95
Tangible Book Value per Share
6
7
9
9
9
10
12
14
14
17
17
18
22
26
20
Basic Weighted Avg Shares
397
1
29
121
178
229
169
1,304
314
642
976
63
31
29
31
Sales/Revenue/Turnover
-35.53
-56,395.08
-2,874.41
-784.46
-483.03
-470.63
-740.18
-39.23
-533.03
-226.39
-123.39
-3,061.62
-5,357.52
-7,090.55
-5,806.68
Operating Margin (%)
17
17
13
17
15
1
2
3
5
6
1
2
1
- -
- -
Depreciation Expense
-103
-636
-739
-857
-931
-1,091
-1,234
-912
-2,095
-1,615
-1,149
-1,939
-1,685
-2,058
-1,825
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-25.92
-53,860.42
-2,566.24
-706.73
-522.34
-476
-732.04
-69.97
-666.85
-251.43
-117.7
-3,075.14
-5,368.27
-7,209.59
-5,813.83
Profit Margin (%)
640
5,398
4,622
3,497
2,542
2,833
2,406
3,303
2,130
3,768
2,287
1,577
2,846
4,024
1,518
Working Capital
228
359
366
325
315
352
312
397
373
262
162
180
187
76
210
LT Debt
472
5,094
4,371
3,501
2,617
2,932
2,901
3,454
2,003
3,594
2,159
1,474
2,752
4,000
1,417
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-213.58
-1,122.63
-174.54
-619.82
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
135
132
156
LT Borrowings
161
139
194
LT Finance Leases
19
17
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
21
21
Market Capitalization
9,820
15,758
10,944

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
1,956
2,057
1,770
Cash, Cash Equivalents & STI
1,533
1,478
1,118
Accounts Receivable, Net
- -
- -
32
Inventories
5
5
4
Total Current Liabilities
379
232
252
Payables & Accruals
- -
- -
- -
ST Debt
135
132
156
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.26%
27.96%
45.34%
Free Cash Flow
51.66%
8.45%
-3.94%
Net Income, GAAP
16.85%
5.2%
22.16%
Sales/Revenue/Turnover
65.04%
0.73%
-9.04%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
31
- -
- -
31
2025
- -
- -
- -
- -
29
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-18.24
- -
- -
- -
-77.17
2025
- -
- -
- -
- -
-80
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Windtree Therapeutics, Inc. (WINTW)
Tyra Biosciences, Inc. (TYRA)
Iovance Biotherapeutics, Inc. (IOVA)
Revance Therapeutics, Inc. (RVNC)
EPIRUS Biopharmaceuticals, Inc. (EPRSQ)
Acro Biomedical Co., Ltd. (ACBM)
Business
Oncolys BioPharma Inc. Oncolys BioPharma Inc. is a biopharmaceutical company focused on the research, development, manufacturing, sale, import, and export of oncolytic viruses, pharmaceuticals, and tumor diagnostic agents targeting cancer and infectious diseases. The company operates through two primary segments, including the pharmaceutical business developing novel therapies such as Telomelysin (OBP-301), a telomerase-specific oncolytic adenovirus in phase II trials for esophageal cancer/gastroesophageal junction tumors by Chugai Pharmaceutical, phase I/II for head and neck cancer combinations with pembrolizumab and radiation, and phase I for hepatocellular carcinoma (HCC) both as monotherapy and combined with atezolizumab plus bevacizumab; OBP-702 for solid tumors in preclinical stages; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor completed in phase IIb for HIV; OBP-801, a histone deacetylase inhibitor in phase I for solid tumors; and diagnostics business offering TelomeScan (OBP-401 and OBP-1101) for detecting circulating tumor cells along with related inspection services. Founded on March 18, 2004, and headquartered in Minato-ku, Tokyo, Japan, with facilities in Kobe, Japan, and subsidiaries Oncolys USA Inc. in New Jersey and OPA Therapeutics Inc., it conducts operations in Japan, the United States, and other Asian regions through licensing agreements with entities including Okayama University, National Cancer Center Hospital East, Cornell University, Medigen Biotechnology Corp., Astellas Pharma Inc., and Chugai Pharmaceutical. Recent developments encompass ongoing clinical progress by partners such as Chugai Pharmaceutical advancing Telomelysin combinations into phase II for esophageal cancer and phase I for HCC and head and neck applications; private placements including 40,000 Series 20 stock acquisition rights issued to EVO FUND in June 2024 for gross proceeds of 2.2 million yen closing July 2024 and additional 43,300 rights at 920 yen each announced in July 2025; and investigator-initiated phase I/b and phase II trials for Telomelysin plus pembrolizumab in advanced solid tumors and esophageal cancers.